Stryker To Buy Inari Medical In $5 Billion Deal To Bolster Venous Thromboembolism Position
Stryker To Buy Inari Medical In $5 Billion Deal To Bolster Venous Thromboembolism Position
Inari's product portfolio complements Stryker's Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism.On Monday, Stryker Corporation (NYSE:SYK) agreed to acquire Inari Medical Inc. (NASDAQ:NARI) for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion.
週一，斯特萊克公司（紐交所：SYK）同意以每股80美元的現金收購Inari Medical Inc.（納斯達克：NARI），這代表了大約49億的完全稀釋股本價值。
Inari, founded in 2011, will help strengthen the peripheral vascular position in the growing segment of venous thromboembolism (VTE) to Stryker.
Inari成立於2011年，將有助於加強Stryker在日益增長的靜脈血栓栓塞（VTE）領域的周邊血管地位。
VTE is a term for blood clots in the veins, which can lead to serious illness, disability, or death.
VTE是指發生在靜脈中的血栓，可能導致嚴重的疾病、殘疾或死亡。
Inari's product portfolio complements Stryker's Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism.
Inari的產品組合補充了Stryker的神經血管業務，包括用於周邊血管疾病（如深靜脈血栓和肺栓塞）的機械取栓解決方案。
Also Read: Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
另請閱讀：摩根士丹利在2024年面臨挫折的情況下維持對醫療科技的積極展望，上調對直覺外科公司和Stryker的評級，下調對Nevro和Glaukos的評級。
Each year, VTE impacts up to 900,000 lives in the United States, with even more affected worldwide. Mechanical thrombectomy for VTE is an estimated $6 billion segment opportunity in the U.S. and is expected to grow 20%+ annually.
每年，VTE在美國影響多達900,000人，全球受影響人數更是更多。用於治療VTE的機械取栓市場在美國的機會估計爲60億美元，預計年增長率超過20%。
Inari products are sold in 30+ countries, with 150,000+ patients treated for VTE.
Inari的產品在30多個國家銷售，已對超過150,000名VTE患者進行了治療。
Analysts estimate Inari's 2024 sales of around $603 million, reflecting 20%+ growth from 2023
分析師估計Inari在2024年的銷售額約爲60300萬美元，比2023年增長超過20%。
People are at particularly high risk for this condition during or just after a hospitalization (with or without surgery), during cancer treatment, and during or just after pregnancy.
人們在住院（無論是否伴隨手術）、接受癌症治療和懷孕期間或剛剛懷孕後，尤其容易面臨這種控制項的高風險。
Inari provides solutions for VTE clot removal without the use of thrombolytic drugs.
Inari提供無溶栓藥物的VTE血栓移除解決方案。
"The acquisition of Inari expands Stryker's portfolio to provide life-saving solutions to patients who suffer from peripheral vascular diseases," said Kevin Lobo, Chair and CEO of Stryker. "These innovations elevate the standard of care for venous thromboembolism patients and will accelerate Stryker's impact in endovascular procedures."
Stryker董事長兼CEO Kevin Lobo表示：「收購Inari擴展了Stryker的產品組合，爲患有外周血管疾病的患者提供挽救生命的解決方案。這些創新提高了靜脈血栓栓塞患者的護理標準，並將加速Stryker在血管內手術中的影響。」
The transaction will be funded with cash on hand and debt and is expected to close by the end of the first quarter of 2025.
此次交易將通過手頭現金和債務進行融資，預計將在2025年第一季度末完成。
Expected impacts to 2025 financial results will be discussed on Stryker's upcoming fourth quarter 2024 earnings call scheduled for January 28, 2025.
對2025年財務結果的預期影響將在Stryker即將於2025年1月28日舉行的2024年第四季度業績發佈會上討論。
Price Action: NARI stock is up 21% at $78.65, and SYK stock is down 1.76% at $355 during the premarket session at last check Tuesday.
價格動態：NARI股票上漲21%，達到78.65美元，而SYK股票在週二的盤前交易中下跌1.76%，達到355美元。
- Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
- 分析師表示，Viking Therapeutics和Structure Therapeutics成爲減肥產品的關鍵製藥合作伙伴。
